Ipca Laboratories and BioSimilar Sciences Partner to Advance Next-Generation Biosimilar Manufacturing in the U.S.
📅 October 2025
Ipca Laboratories Ltd. (NSE: IPCA) and BioSimilar Sciences PR LLC (BSS) have announced a definitive Technology Transfer and Joint Development Agreement to accelerate the development of Ipca’s next-generation anti-cancer and anti-inflammatory monoclonal antibody biosimilar.
Under this agreement, the late-stage development, clinical manufacturing, and commercial supply of the biosimilar will be conducted at BSS’s 200,000-square-foot sterile facility in Aguadilla, Puerto Rico — a key hub for biologics innovation and manufacturing in the U.S.
Bridging Indian Innovation and U.S. Manufacturing Strength
This collaboration represents a major step in strengthening the biologics manufacturing ecosystem by combining Ipca’s scientific expertise in biosimilar development with BSS’s world-class infrastructure and regulatory capabilities.
“We’re turning decades of Indian innovation into American manufacturing muscle — exactly the sort of on-shoring that boosts the economy and puts life-saving biologics within reach of U.S. patients,” said Robert J. Salcedo, Co-Founder and CEO of BioSimilar Sciences. “This deal leverages BSS’s scientific capability while utilizing OcyonBio’s advanced sterile filling capacity.”
Accelerating Affordable Biologics for Global Patients
Through this partnership, Ipca and BSS aim to streamline biosimilar production, reduce development timelines, and enhance access to affordable biologics for patients suffering from cancer and autoimmune diseases worldwide.
“By pairing Ipca’s established science with Puerto Rico’s skilled workforce and BSS’s regulatory expertise, we’re accelerating affordable biologies for people battling cancer and autoimmune disease globally,” said Pranay Godha, MD & CEO, Ipca Laboratories.
A Strategic Alliance for Next-Gen Biologics
The collaboration highlights an emerging model of cross-border innovation and localized manufacturing, aligning with global priorities for supply chain resilience, biopharma self-reliance, and cost-effective biologic therapies.
With this partnership, Ipca Laboratories strengthens its position in the biosimilar development landscape, while BioSimilar Sciences reinforces Puerto Rico’s growing role as a biomanufacturing powerhouse serving global healthcare needs.
Explore more
🎤 Career – Real career stories and job profiles of life science professionals. Discover current opportunities for students and researchers.
💼 Jobs – The latest job openings and internship alerts across academia and industry.
📢 Advertise with BioPatrika – Reach the Right Audience, Fast!
🛠️ Services – Regulatory support, patent filing assistance, and career consulting services.
